Bicara Therapeutics Inc. (BCAX) 8-K Current Report — February 26, 2026
Filed: February 26, 2026
Health Care
Pharmaceutical PreparationsBicara Therapeutics Inc. (BCAX) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 2.02: Results of Operations and Financial Condition
Bicara Therapeutics Inc. 8-K Feb 26, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Net proceeds ~$161.8M from offering of 7,175,000 firm shares + 2,200,000 pre-funded warrants at $16.00/share public price
- • Underwriters exercised full 30-day overallotment option (1,406,250 additional shares) on Feb 25, 2026 — signals strong institutional demand
Item 2.02 · Results of Operations and Financial Condition
- • Cash, cash equivalents, and investments ~$414.8M as of Dec 31, 2025 — preliminary, unaudited figure
- • Disclosed in connection with an active equity offering (prospectus supplement), signaling dilution risk
Get deeper insights on Bicara Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.